|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: POLR3H |
Gene summary for POLR3H |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | POLR3H | Gene ID | 171568 |
| Gene name | RNA polymerase III subunit H | |
| Gene Alias | C25 | |
| Cytomap | 22q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | A0A024R1P3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 171568 | POLR3H | LZE2T | Human | Esophagus | ESCC | 1.83e-02 | 4.19e-01 | 0.082 |
| 171568 | POLR3H | LZE7T | Human | Esophagus | ESCC | 4.48e-05 | 1.67e-01 | 0.0667 |
| 171568 | POLR3H | LZE20T | Human | Esophagus | ESCC | 1.04e-04 | 1.29e-01 | 0.0662 |
| 171568 | POLR3H | LZE24T | Human | Esophagus | ESCC | 5.40e-09 | 2.84e-01 | 0.0596 |
| 171568 | POLR3H | P1T-E | Human | Esophagus | ESCC | 1.61e-08 | 3.52e-01 | 0.0875 |
| 171568 | POLR3H | P2T-E | Human | Esophagus | ESCC | 4.13e-10 | 2.30e-01 | 0.1177 |
| 171568 | POLR3H | P4T-E | Human | Esophagus | ESCC | 1.48e-28 | 7.53e-01 | 0.1323 |
| 171568 | POLR3H | P5T-E | Human | Esophagus | ESCC | 1.63e-23 | 5.35e-01 | 0.1327 |
| 171568 | POLR3H | P8T-E | Human | Esophagus | ESCC | 4.95e-13 | 3.55e-01 | 0.0889 |
| 171568 | POLR3H | P9T-E | Human | Esophagus | ESCC | 4.78e-19 | 4.38e-01 | 0.1131 |
| 171568 | POLR3H | P10T-E | Human | Esophagus | ESCC | 3.56e-37 | 7.12e-01 | 0.116 |
| 171568 | POLR3H | P11T-E | Human | Esophagus | ESCC | 1.48e-13 | 5.27e-01 | 0.1426 |
| 171568 | POLR3H | P12T-E | Human | Esophagus | ESCC | 9.74e-17 | 3.19e-01 | 0.1122 |
| 171568 | POLR3H | P15T-E | Human | Esophagus | ESCC | 1.58e-18 | 4.62e-01 | 0.1149 |
| 171568 | POLR3H | P16T-E | Human | Esophagus | ESCC | 7.00e-24 | 5.42e-01 | 0.1153 |
| 171568 | POLR3H | P17T-E | Human | Esophagus | ESCC | 3.32e-08 | 3.69e-01 | 0.1278 |
| 171568 | POLR3H | P19T-E | Human | Esophagus | ESCC | 6.00e-09 | 7.89e-01 | 0.1662 |
| 171568 | POLR3H | P20T-E | Human | Esophagus | ESCC | 6.51e-13 | 2.27e-01 | 0.1124 |
| 171568 | POLR3H | P21T-E | Human | Esophagus | ESCC | 4.75e-30 | 5.95e-01 | 0.1617 |
| 171568 | POLR3H | P22T-E | Human | Esophagus | ESCC | 3.67e-42 | 7.96e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:00063833 | Esophagus | ESCC | transcription by RNA polymerase III | 41/8552 | 46/18723 | 7.69e-10 | 1.90e-08 | 41 |
| GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:0006352 | Liver | HCC | DNA-templated transcription, initiation | 78/7958 | 130/18723 | 4.19e-05 | 4.11e-04 | 78 |
| GO:0006383 | Liver | HCC | transcription by RNA polymerase III | 31/7958 | 46/18723 | 5.67e-04 | 3.61e-03 | 31 |
| GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
| GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:00063832 | Oral cavity | OSCC | transcription by RNA polymerase III | 34/7305 | 46/18723 | 1.61e-06 | 2.11e-05 | 34 |
| GO:00063522 | Oral cavity | OSCC | DNA-templated transcription, initiation | 74/7305 | 130/18723 | 2.56e-05 | 2.39e-04 | 74 |
| GO:000961516 | Oral cavity | LP | response to virus | 143/4623 | 367/18723 | 7.42e-10 | 3.52e-08 | 143 |
| GO:005160711 | Oral cavity | LP | defense response to virus | 97/4623 | 265/18723 | 9.31e-06 | 1.74e-04 | 97 |
| GO:014054611 | Oral cavity | LP | defense response to symbiont | 97/4623 | 265/18723 | 9.31e-06 | 1.74e-04 | 97 |
| GO:00063831 | Oral cavity | LP | transcription by RNA polymerase III | 20/4623 | 46/18723 | 4.03e-03 | 2.61e-02 | 20 |
| GO:00063521 | Oral cavity | LP | DNA-templated transcription, initiation | 45/4623 | 130/18723 | 7.03e-03 | 3.96e-02 | 45 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0302021 | Esophagus | ESCC | RNA polymerase | 28/4205 | 34/8465 | 8.19e-05 | 3.35e-04 | 1.71e-04 | 28 |
| hsa046234 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa0302031 | Esophagus | ESCC | RNA polymerase | 28/4205 | 34/8465 | 8.19e-05 | 3.35e-04 | 1.71e-04 | 28 |
| hsa0462311 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa03020 | Liver | HCC | RNA polymerase | 24/4020 | 34/8465 | 5.40e-03 | 1.57e-02 | 8.75e-03 | 24 |
| hsa030201 | Liver | HCC | RNA polymerase | 24/4020 | 34/8465 | 5.40e-03 | 1.57e-02 | 8.75e-03 | 24 |
| hsa030204 | Oral cavity | OSCC | RNA polymerase | 25/3704 | 34/8465 | 4.12e-04 | 1.27e-03 | 6.45e-04 | 25 |
| hsa04623 | Oral cavity | OSCC | Cytosolic DNA-sensing pathway | 44/3704 | 75/8465 | 6.44e-03 | 1.51e-02 | 7.68e-03 | 44 |
| hsa0302011 | Oral cavity | OSCC | RNA polymerase | 25/3704 | 34/8465 | 4.12e-04 | 1.27e-03 | 6.45e-04 | 25 |
| hsa046231 | Oral cavity | OSCC | Cytosolic DNA-sensing pathway | 44/3704 | 75/8465 | 6.44e-03 | 1.51e-02 | 7.68e-03 | 44 |
| hsa030202 | Oral cavity | LP | RNA polymerase | 18/2418 | 34/8465 | 2.35e-03 | 1.03e-02 | 6.63e-03 | 18 |
| hsa046232 | Oral cavity | LP | Cytosolic DNA-sensing pathway | 31/2418 | 75/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 31 |
| hsa030203 | Oral cavity | LP | RNA polymerase | 18/2418 | 34/8465 | 2.35e-03 | 1.03e-02 | 6.63e-03 | 18 |
| hsa046233 | Oral cavity | LP | Cytosolic DNA-sensing pathway | 31/2418 | 75/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 31 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| POLR3H | SNV | Missense_Mutation | novel | c.131N>C | p.Leu44Pro | p.L44P | Q9Y535 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| POLR3H | SNV | Missense_Mutation | novel | c.130N>A | p.Leu44Ile | p.L44I | Q9Y535 | protein_coding | deleterious(0) | possibly_damaging(0.856) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| POLR3H | deletion | Frame_Shift_Del | novel | c.476_492delACACGTCCCCCACAGGG | p.Asp159AlafsTer11 | p.D159Afs*11 | Q9Y535 | protein_coding | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| POLR3H | SNV | Missense_Mutation | novel | c.400N>A | p.Glu134Lys | p.E134K | Q9Y535 | protein_coding | deleterious(0.04) | possibly_damaging(0.71) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| POLR3H | SNV | Missense_Mutation | c.224T>C | p.Val75Ala | p.V75A | Q9Y535 | protein_coding | deleterious(0) | possibly_damaging(0.457) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| POLR3H | SNV | Missense_Mutation | c.365N>G | p.Glu122Gly | p.E122G | Q9Y535 | protein_coding | deleterious(0.02) | possibly_damaging(0.71) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| POLR3H | SNV | Missense_Mutation | rs531455869 | c.217C>T | p.Arg73Cys | p.R73C | Q9Y535 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| POLR3H | SNV | Missense_Mutation | c.244N>T | p.Asp82Tyr | p.D82Y | Q9Y535 | protein_coding | deleterious(0.04) | probably_damaging(0.928) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| POLR3H | SNV | Missense_Mutation | novel | c.446N>A | p.Arg149His | p.R149H | Q9Y535 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-E6-A2P9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| POLR3H | SNV | Missense_Mutation | rs763860979 | c.433N>A | p.Gly145Ser | p.G145S | Q9Y535 | protein_coding | deleterious(0.02) | probably_damaging(0.909) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |